Deutsche Bank Remains a Hold on Sanofi (SNYNF)

TipRanksMar 4 07:36 ET · Ratings

Top Gap Ups and Downs on Monday: SNY, GFI, LI and More

Moomoo NewsMar 3 18:00 ET · Markets

Top HHS Spokesman Tom Corry Abrupty Resigns

Seeking AlphaMar 3 15:13 ET

Apogee Therapeutics' Investigational Atopic Dermatitis Potential Shows Strong Tolerability, Extended Half-Life in Early Trial

BenzingaMar 3 12:16 ET

Is Sanofi (SNY) The Best Immunology Stock To Buy Now?

Yahoo FinanceMar 1 14:40 ET

Sanofi and Teva Reveal Promising Duvakitug Study Results at ECCO 2025

TipRanksFeb 28 06:27 ET

Media Update: AAD: New Data Advance Sanofi's Scientific Leadership Across Innovative Treatments for Inflammatory Skin Diseases

SanofiFeb 28 00:00 ET

Sanofi India Reports Strong Financial Results and Proposes Dividend

TipRanksFeb 27 19:24 ET

Novavax Reports Smaller Q4 Loss, Shifts Focus From Commercializing COVID-19 Vaccine To Maximize Value

BenzingaFeb 27 11:24 ET

Novavax Stock Rises as Revenue Beat Estimates

Barron'sFeb 27 10:52 ET · Movers

Novavax Posts Q4 Revenue Beat Despite 80% Drop in Product Sales

Seeking AlphaFeb 27 08:49 ET

FDA AdCom Meeting on Flu Vaccines Canceled

Seeking AlphaFeb 27 06:33 ET

Sanofi's Sustained Revenue Growth Potential: Buy Rating Justified by Extended Amvuttra Royalties

TipRanksFeb 27 04:37 ET · Ratings

CDC A(H5N1) Bird Flu Response Update February 26, 2025; Confirmed 3 Human Cases Of H5 Bird Flu In People Who Became Ill In 2025 - Website

BenzingaFeb 26 13:20 ET

U.S. to Spend up to $1B for Bird Flu Response

Seeking AlphaFeb 26 12:11 ET

Scribe Therapeutics to Participate in Upcoming Conferences

BusinesswireFeb 26 09:00 ET

Enveda Gains Backing From Sanofi to Advance AI-Driven Drug Discovery to Clinical Trials Bringing Total Series C Financing to $150M

BusinesswireFeb 26 09:00 ET

Sanofi Target Raised to EUR125 From EUR100 by Intron Health

Dow JonesFeb 26 01:10 ET · Ratings

Sanofi Raised to Buy From Hold by Intron Health

Dow JonesFeb 26 01:10 ET · Ratings

Duvakitug, co-developed by Sanofi (SNY.US) and Teva (TEVA.US), is expected to enter phase 3 clinical trials in the second half of the year.

Sanofi (SNY.US) and Teva (TEVA.US) recently announced the detailed results obtained from their jointly developed monoclonal antibody duvakitug in the phase 2 clinical trial RELIEVE UCCD.

Zhitong FinanceFeb 25 01:33 ET